Zhong Guo Ji Jin Bao·2025-11-06 14:44Core Points - The China Securities Index Co., Ltd. will officially launch the China Securities Innovation Drug Index and the China Securities Innovation Medical Device Index on November 7, providing more investment options for the market [1][2]. Group 1: Innovation Drug Index - The China Securities Innovation Drug Index selects listed companies involved in innovative drug research and development from the Sci-Tech Innovation Board and the Growth Enterprise Market, reflecting the overall performance of these companies [3]. - A total of 50 constituent stocks have been included in the index, such as BeiGene, Bairui Tianheng, and Kanglong Chemical [3]. - Notable stocks include: - BeiGene-U: Latest closing price of 277.50 CNY, year-to-date increase of 72.34%, and total market value of 279.45 billion CNY [4]. - Bairui Tianheng: Latest closing price of 361.50 CNY, year-to-date increase of 88.55%, and total market value of 149.25 billion CNY [4]. - Kanglong Chemical: Latest closing price of 32.25 CNY, year-to-date increase of 26.52%, and total market value of 54.40 billion CNY [4]. Group 2: Medical Device Index - The China Securities Innovation Medical Device Index selects listed companies providing medical devices, consumables, and in vitro diagnostics from the Sci-Tech Innovation Board and the Growth Enterprise Market, reflecting the overall performance of these companies [5]. - A total of 50 constituent stocks have been included in the index, such as Mindray Medical, New Industry, and Aimeike [5]. - Notable stocks include: - Mindray Medical: Latest closing price of 206.35 CNY, year-to-date decrease of 17.92%, and total market value of 250.19 billion CNY [6]. - New Industry: Latest closing price of 61.98 CNY, year-to-date decrease of 10.53%, and total market value of 48.70 billion CNY [7]. - Aimeike: Latest closing price of 152.00 CNY, year-to-date decrease of 14.30%, and total market value of 45.99 billion CNY [7]. Group 3: Market Trends - The pharmaceutical sector has attracted significant investor attention this year, particularly in the innovative drug space, which has shown remarkable performance [8]. - China's innovative drug pipeline and clinical trial projects rank among the top globally, with ongoing policy support aimed at promoting high-quality industry development [8]. - The medical device industry is also experiencing rapid growth, driven by innovation and the trend of import substitution, as well as global expansion [9].